D. Hargrove

发表

Biological activity of AC3174, a peptide analog of exendin-4

C. Anderson, S. Flanagan, B. Gedulin, 2007, Regulatory Peptides.

Effects of dietary excesses of the branched-chain amino acids on growth, food intake and plasma amino acid concentrations of kittens.

D. Hargrove, Q. Rogers, J. Morris, 1988, The Journal of nutrition.

Enhanced peripheral glucose utilization in transgenic mice expressing the human GLUT4 gene.

R. McPherson, J. Treadway, J. Pessin, 1994, The Journal of biological chemistry.

GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure.

T. Reynolds, S. Cushman, J. Brozinick, 2001, Diabetes.

In vitro and in vivo characterization of 3-[2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl]benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist.

T. Maurer, D. Hargrove, C. Mack, 2003, Journal of medicinal chemistry.

Role of insulin in the blunted glucose metabolic response of septic rats to epinephrine.

J. Spitzer, C. Lang, G. Bagby, 1990, Metabolism: clinical and experimental.

Glucose kinetics in rats infused with endotoxin-induced monokines or tumor necrosis factor.

J. J. Thompson, J. Spitzer, C. Lang, 1988, Circulatory shock.

A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents

B. Gedulin, C. Jodka, D. Parkes, 2013, Diabetes, obesity & metabolism.

Alterations in glucose kinetics induced by pentobarbital anesthesia.

J. Spitzer, C. Lang, G. Bagby, 1986, The American journal of physiology.

Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism.

J. Spitzer, C. Lang, G. Bagby, 1988, The American journal of physiology.

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

B. Gedulin, D. Parkes, D. Hargrove, 2010, American journal of physiology. Endocrinology and metabolism.

Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration.

D. Hargrove, N. A. Nardone, R. W. Stevenson, 1995, Metabolism: clinical and experimental.

Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome

P. Rivière, D. Hargrove, Karthik Srinivasan, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

P. Rivière, Yung-Chih Wang, J. J. Dwyer, 2016, Journal of medicinal chemistry.

Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo.

D. Hargrove, N. A. Nardone, R. W. Stevenson, 1996, Metabolism: clinical and experimental.

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

D. Scott, D. Hargrove, R. L. Dow, 2010, Biochemical and biophysical research communications.

Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine.

T. Kohout, D. Hargrove, Karthik Srinivasan, 2021, Journal of pharmaceutical sciences.

Platelet-activating factor-induced increases in glucose kinetics.

J. Spitzer, C. Lang, C. Dobrescu, 1988, The American journal of physiology.

Adrenergic blockade does not abolish elevated glucose turnover during bacterial infection.

J. Spitzer, C. Lang, G. Bagby, 1988, The American journal of physiology.

Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists.

P. Rivière, D. Hargrove, J. Kraus, 2019, Journal of medicinal chemistry.

Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.

T. Maurer, D. Hargrove, R. L. Dow, 2004, Bioorganic & medicinal chemistry letters.

Modulation of insulin secretion and glycemia by selective inhibition of cyclic AMP phosphodiesterase III.

D. Hargrove, N. A. Nardone, J. Parker, 1997, Biochemical and biophysical research communications.

Tissue glucose utilization during epinephrine-induced hyperglycemia.

J. Spitzer, C. Lang, D. Hargrove, 1989, Journal of applied physiology.

Alterations in the metabolic control of carbohydrates in sepsis.

J. Spitzer, C. Lang, G. Bagby, 1989, Progress in clinical and biological research.

Leucine and isoleucine requirements of the kitten

D. Hargrove, Q. Rogers, J. Morris, 1984, British Journal of Nutrition.

The tryptophan requirement of the kitten

D. Hargrove, Q. Rogers, J. Morris, 1983, British Journal of Nutrition.

An arginine-deficient diet in humans does not evoke hyperammonemia or orotic aciduria.

S. Brusilow, D. Hargrove, Q. Rogers, 1987, The Journal of nutrition.

Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured Cells and in Experimental Animals*

D. Hargrove, D. Dalvie, J. Chapman, 2003, Journal of Biological Chemistry.

Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.

T. Maurer, D. Hargrove, C. Mack, 2011, Bioorganic & medicinal chemistry letters.

Epinephrine-induced increase in glucose turnover is diminished during sepsis.

J. Spitzer, C. Lang, G. Bagby, 1989, Metabolism: clinical and experimental.

Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.

T. Maurer, D. Hargrove, D. Tess, 2007, Bioorganic & medicinal chemistry letters.

Kittens choose a high leucine diet even when isoleucine and valine are the limiting amino acids.

D. Hargrove, Q. Rogers, J. Morris, 1994, The Journal of nutrition.

Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists.

Eunsun Lee, D. Hargrove, B. Morgan, 2002, Journal of medicinal chemistry.

Additive effect of simultaneous continuous administration of degarelix and TAK‐448 on LH suppression in a castrated rat model

T. Kohout, D. Hargrove, A. Kamal, 2018, European journal of pharmacology.

Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist.

J. Spitzer, C. Lang, C. Dobrescu, 1987, Circulatory shock.

Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.

A. Kalgutkar, T. Maurer, D. Scott, 2010, Bioorganic & medicinal chemistry letters.

Glucose transport-enhancing and hypoglycemic activity of 2-methyl-2-phenoxy-3-phenylpropanoic acids.

J. Treadway, J. Blake, E. M. Gibbs, 1996, Journal of medicinal chemistry.

Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics.

Peter Cornelius, Eunsun Lee, Dennis E Danley, 2003, Bioorganic & medicinal chemistry letters.